Continuing Education Activity

Postthrombotic syndrome (PTS) is a form of chronic venous insufficiency that develops after an episode of acute deep vein thrombosis (DVT). Common symptoms of PTS include leg discomfort, heaviness, vein dilation, edema, skin discoloration, and venous ulcers. Despite adequate anticoagulation therapy, PTS affects 20% to 50% of patients with DVT. This condition represents a significant public health concern due to its considerable impact on both quality of life and healthcare costs. The diagnosis of this condition is based on clinical assessment, with the Villalta score used to evaluate the severity of symptoms. Management of PTS focuses on symptom relief through compression therapy, exercise, and pain control, while severe cases may require endovascular or surgical interventions.

Complications include chronic pain, persistent swelling, skin changes, and venous ulcers, which can lead to recurrent infections and reduced mobility. Prognosis varies, with some patients experiencing mild symptoms, whereas others develop severe, debilitating diseases. Early intervention and adherence to management strategies improve outcomes, but no definitive cure exists. While long-term care is essential, it remains an area of ongoing research despite expanding knowledge on PTS. This activity focuses on evaluating and managing PTS, covering its epidemiology, pathophysiology, clinical presentation, and recommended diagnostic and therapeutic approaches. This activity also highlights the importance of collaboration among healthcare providers, emphasizing the need for effective teamwork to optimize care for patients with this complex disorder.

Objectives:

• Identify the clinical signs and symptoms of postthrombotic syndrome to recognize early manifestations in patients with a history of deep vein thrombosis.
• Implement evidence-based therapeutic strategies, including lifestyle modifications and pharmacological interventions, to manage progression and alleviate symptoms of postthrombotic syndrome.
• Apply therapeutic interventions such as compression-based therapy and pharmacological treatments to manage postthrombotic syndrome symptoms.
• Collaborate with interprofessional healthcare providers, including vascular specialists and physical therapists, to develop a comprehensive care plan for patients with postthrombotic syndrome.

Introduction

Postthrombotic syndrome (PTS) is a complication of acute deep vein thrombosis (DVT) that presents with signs and symptoms of chronic venous insufficiency. PTS is characterized by leg discomfort, heaviness, vein dilation, edema, skin discoloration, and venous ulcers. DVT affects approximately 1 in 1000 individuals annually, and despite appropriate anticoagulation, PTS develops in 20% to 50% of cases.[1][2]

PTS is a significant public health concern due to its profound impact on quality of life and healthcare costs. The socioeconomic repercussions of PTS are expected to increase in the coming years. While notable advances have been made in understanding the condition, many unresolved questions remain. Effective and validated treatment protocols for PTS are still under development. Current management strategies focus on preventing DVT, ensuring prompt identification, and reducing the risk of recurrence.[3]

Etiology

The etiology of PTS is not well understood. However, the disorder is believed to result from venous hypertension caused by valvular impairment and restricted venous outflow due to persistent thrombosis and fibrosis of the vessel wall. An acute DVT episode leads to partial or complete venous flow restriction, and failure to recanalize—often observed as early as 6 weeks after diagnosis—results in persistent obstruction and fibrotic damage to the venous wall.[4]

The inflammatory cascade also contributes to direct venous valve damage.[5][6] These postthrombotic changes increase venous pressure, which is transmitted to capillary beds, leading to tissue swelling, lipodermatosclerosis, and, eventually, tissue oxygen deprivation and venous ulcer formation.[7] Recent studies suggest that concurrent arterial disease may also occur with DVT, leading to stiffness and associated symptoms, although the exact mechanism behind this relationship remains unclear.[8]

Epidemiology

Comprehensive epidemiological data on PTS are limited, but some studies report an incidence of 20% to 50% in patients with a history of DVT.[9] Approximately 8% to 10% of cases are severe, significantly reducing the quality of life of affected individuals.[10] A systematic review of 16 cohort studies found variation in occurrence rates across different countries, with an overall 2-year incidence of PTS at 37.5%.[11] Additionally, a registry of 1107 patients with proximal DVT showed a 3-year incidence of 27.8%, with older patients exhibiting a higher incidence and increased prevalence of persistent DVT risk factors.

Another potential contributor to the development of PTS is the presence of varicose veins, which has been observed in female patients only. Studies have also indicated that the occurrence of PTS levels off between 1 and 2 years after an acute DVT episode, although symptoms can emerge within 6 years in approximately one-third of patients.[12]

History and Physical

PTS can present with a range of symptoms, from mild, such as skin pigmentation, telangiectasia, minor discomfort, and edema, to severe, including chronic pain, significant anterior tibial edema, and skin ulceration. Symptoms may develop within weeks or months after a DVT episode or persist from the acute phase of DVT.[13] Edema affects approximately two-thirds of individuals with PTS and is often accompanied by limb heaviness and discomfort, especially after prolonged standing or walking. These symptoms can typically be alleviated by resting or elevating the limb.

Approximately one-third of individuals experience skin changes, including discoloration, telangiectasia, eczema, varicose veins, and lipodermatosclerosis. Ulceration occurs in less than 5% of patients. Dermatological alterations typically manifest 2 to 4 years after an acute DVT episode.[14]

Evaluation

The diagnosis of PTS is primarily based on clinical assessment, as no gold standard test currently exists. Ongoing research is investigating serum biomarkers, including intercellular adhesion molecule-1 (ICAM-1) and matrix metalloproteinases 1 (MMP-1) and 8 (MMP-8), as potential predictors of PTS.[15] The neutrophil-to-lymphocyte ratio is also being investigated for its applicability in iliofemoral DVT.[16] Further diagnostic testing is typically unnecessary, and PTS should be suspected in patients with a history of DVT.[17]

Several clinical scores assist in diagnosing and characterizing PTS. The Villalta scale, developed in 1994, classifies the condition based on severity, incorporating 6 subjective symptoms, 6 objective signs, and the presence of venous ulceration (see the Table below).[18] The presence of a venous ulcer or a score greater than 5 confirms the diagnosis of PTS. A score between 5 and 10 indicates mild disease, 10 to 14 indicates moderate disease, and 15 or higher reflects severe disease.[19][20] The International Society on Thrombosis and Haemostasis recommends using the Villalta score at the initial visit to diagnose PTS and again after 3 months to assess severity and progression.[21]

The Villalta scale is the primary clinical tool for evaluating lower-extremity PTS. However, the condition can also affect the upper extremities, where the upper-extremity PTS (UE-PTS) score is used.[22] This score assesses 5 symptoms—edema, heaviness, fatigue upon use, pain, and functional arm limitations—along with 3 clinical signs—asymmetrical arm circumference, discoloration at rest, and collateral veins around the shoulder, torso, or breast. The Villalta scale categorizes PTS as absent, mild, moderate, or severe.[23] Some sources suggest that patients with mild disease may be overlooked due to subtle symptoms, potentially leading to suboptimal treatment.

The shortened Disabilities of the Arm, Shoulder, and Hand Questionnaire (QuickDASH) is an 11-item tool used for assessing physical function and symptoms in individuals with upper-extremity musculoskeletal disorders, including UE-PTS. The questionnaire covers daily activities, housework, shopping, recreation, self-care, food preparation, sleep, social interactions, job performance, pain, and tingling or numbness.[24] The International Delphi consensus recommends incorporating the QuickDASH questionnaire to evaluate UE-PTS.

Venous abnormalities, including residual obstruction or proximal venous reflux, should be evaluated in patients with severe symptoms to determine the need for intervention. The primary imaging modalities for this assessment include venous duplex ultrasound, intravascular ultrasonography, and venography.[25] Patients with a history of DVT who remain asymptomatic despite imaging findings of persistent venous obstruction or venous hypertension do not meet the diagnostic criteria for PTS.[26]

Table

Table. The Villalta Scale .

Treatment / Management

The primary modalities for PTS management include exercise, limb elevation, and compression therapy. However, additional interventional studies are needed to determine the most effective treatment approach.[27]

Exercise enhances venous blood flow, reducing venous stasis and hypercoagulability—key factors in thrombosis development.[28] Recent studies suggest that exercise does not increase the risk of pulmonary embolism in patients with DVT. An inferior vena cava (IVC) filter may be considered in high-risk patients.[29] Physical activity helps alleviate symptoms, and resistance training has been shown to improve muscle strength and walking performance by reducing thrombus size and accelerating its dissolution.[30]

Compression-based therapies help alleviate symptoms and improve daily functionality.[31] These therapies counteract the transcurrent damage caused by venous stasis and hypertension, which result from factors such as delayed outflow, thrombosis, valvular damage, and venous wall scarring (reflux type). Compression therapies offer significant benefits by reducing capillary leakage and edema, supporting venous valvular function, and enhancing skin microcirculation through muscular compression.

Depending on the severity of symptoms and the presence of edema, skin abnormalities, or ulceration, various compression modalities may be used, including compression socks, short stretch bandages, multilayer compression, and zinc paste bandages.[32] For patients with moderate-to-severe PTS who do not experience relief from elastic compression stockings alone, a portable intermittent compression device may be considered as an additional therapeutic option.[33][34] 

Pharmacological therapy, including venoactive drugs such as diosmin and rutosides, is used to manage lower extremity symptoms in PTS. However, high-quality data from randomized trials are insufficient to support the widespread use of pharmacological interventions for PTS.

Local management of skin changes and venous ulcers is essential in treating PTS. Moisturizers and midpotency topical corticosteroids help address dry skin, itching, and eczematous changes, while dressings promote moist wound healing for ulcers.[35]

A randomized clinical trial involving 208 patients with acute lower extremity DVT, divided equally into 4 groups (warfarin alone, warfarin plus rosuvastatin, rivaroxaban alone, and rivaroxaban plus rosuvastatin), found that those taking rosuvastatin experienced a more significant reduction in inflammatory marker levels compared to those on anticoagulants alone (P < .0001). A significant change in lower limb size was observed in 3 groups 3 months after DVT, with the rosuvastatin groups showing a more notable decrease in limb size than those on anticoagulation alone (P < .0001 versus P < .05).[36] The literature generally favors the use of direct oral anticoagulants (DOACs) over low-molecular-weight heparins (LMWH) and vitamin K antagonists for treating upper extremity thromboses, as DOACs are associated with a reduced risk of PTS.[37]

Vascular procedures may be necessary if severe symptoms persist and venous obstruction or reflux is present. Interventions such as percutaneous angioplasty with or without stenting, venous bypass, and endophlebectomy can help reduce ulcer recurrence and skin alterations, thereby improving patients' quality of life.[38][39] Studies have demonstrated that eliminating the source of retrograde flow can improve venous hemodynamics.[40][41]

Although stenting can improve vascular flow and promote ulcer healing, it has notable risks.[42] Mechanical pressure and stress may cause stent fracture, and improper placement could lead to stent migration within the vessel. Stents can cause contralateral thrombosis, a condition known as "jailing," in which an iliac stent obstructs flow through an IVC filter, thereby impeding circulation in the opposite iliac system. Additionally, back pain may develop if the placement site induces venous distortion that compresses surrounding tissues, such as nerves.

Prompt treatment of acute DVT is essential in preventing PTS. A meta-analysis comparing various anticoagulants showed that edoxaban was more effective than rivaroxaban in preventing PTS.[43]

Differential Diagnosis

PTS manifestations, such as lower extremity pain, heaviness, and edema, are also seen in various conditions, including primary venous insufficiency, increased body mass index (BMI), lipedema, lymphedema, soft tissue masses, and posttraumatic changes. A prior history of DVT can help differentiate PTS from primary venous insufficiency. While PTS symptoms are typically isolated to the limb where the DVT occurred, primary venous insufficiency tends to occur bilaterally.

Masses causing venous obstruction, such as arterial aneurysms, Baker cysts, and soft tissue tumors, may be readily detectable during physical examination of the groin and popliteal fossa. However, these growths can be challenging to detect in patients with obesity or significant limb swelling. Ultrasound or cross-sectional imaging techniques can help detect and distinguish these lesions.

Prognosis

Despite recent advancements, PTS remains one of the most prevalent, chronic, and debilitating complications of acute DVT, with limited treatment options. More than 50% of patients prescribed elastic compression stockings and receiving appropriate follow-up experience stability or improvement, regardless of the initial severity of the syndrome.[44]

However, some studies present mixed evidence regarding the benefits of elastic compression stockings. For example, the largest placebo-controlled trial, the Study on the Efficacy of Stockings (SOX) for PTS, failed to show a significant interventional effect. In the trial, 14.2% of patients using elastic compression stockings developed PTS compared to 12.7% in the placebo group. However, these results may be influenced by low compliance rates due to factors such as discomfort, cost, and difficulty in putting on the stockings.

Complications

A proximal DVT is associated with a greater risk of occurrence and more severe PTS symptoms compared to distal DVT.[45] However, complications in both types primarily affect patients who continue to experience the initial venous symptoms associated with DVT. Notably, catheter-directed thrombolysis complicated by PTS in acute lower DVT is more common in patients with a BMI greater than 24.33 kg/m², mixed DVT, a history of varicose veins, and an IVC filter, among other factors.[46]

Leg ulceration is a major complication of PTS, contributing to significant disability and financial burdens for both individuals and healthcare systems. Venous ulcers are typically painless, superficial lesions with irregular borders, red granulation tissue, yellow fibrin at the base, and exudates. Poor prognostic factors for ulcer healing include a duration longer than 3 months, an initial size greater than 10 cm, the presence of arterial disease, advanced age, and an elevated BMI. The patient's quality of life, a subjective measure, is greatly influenced by the prevention, detection, and management of complications such as PTS.

Deterrence and Patient Education

The following measures are recommended to prevent PTS:

• Regular ambulation
• Frequent physical activity
• Use of compression stockings
• Adherence to anticoagulation therapy after an acute DVT

By emphasizing these practical strategies, healthcare providers can better support patients adhering to them. As with all aspects of medicine, education fosters compliance.

Enhancing Healthcare Team Outcomes

Collaboration among healthcare providers, including physicians, nurses, and physical therapists, is essential for delivering patient-centered care for PTS. Healthcare professionals must have the clinical skills and expertise required to diagnose, evaluate, and treat the condition effectively. Key competencies include identifying PTS symptoms, recognizing potential complications, and implementing appropriate management strategies. Depending on the severity of the symptoms, consultation with a vascular surgery specialist may be necessary. A personalized care plan tailored to each patient's unique needs is crucial for mitigating complications such as venous ulcers.

Interprofessional healthcare team members must understand their roles and actively contribute their specialized expertise to the care plan. Effective communication within the team is essential for smooth information exchange and collaborative decision-making. By adopting the best practices in communication and care coordination, healthcare professionals can improve patient outcomes and enhance team performance in managing PTS.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Bruning G, Woitalla-Bruning J, Queisser AC, Buhr JK. Diagnosis and Treatment of Postthrombotic Syndrome. Hamostaseologie. 2020 Jun;40(2):214-220. [PubMed: 32455461]

2.

Makedonov I, Kahn SR, Abdulrehman J, Schulman S, Delluc A, Gross P, Galanaud JP. Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review. Thromb Haemost. 2022 Aug;122(8):1255-1264. [PubMed: 34852380]

3.

Wang J, Smeath E, Lim HY, Nandurkar H, Kok HK, Ho P. Current challenges in the prevention and management of post-thrombotic syndrome-towards improved prevention. Int J Hematol. 2023 Nov;118(5):547-567. [PMC free article: PMC10615940] [PubMed: 37651058]

4.

Chandrashekar A, Garry J, Gasparis A, Labropoulos N. Vein wall remodeling in patients with acute deep vein thrombosis and chronic postthrombotic changes. J Thromb Haemost. 2017 Oct;15(10):1989-1993. [PubMed: 28787773]

5.

Shahneh F, Christian Probst H, Wiesmann SC, A-Gonzalez N, Ruf W, Steinbrink K, Raker VK, Becker C. Inflammatory Monocyte Counts Determine Venous Blood Clot Formation and Resolution. Arterioscler Thromb Vasc Biol. 2022 Feb;42(2):145-155. [PubMed: 34911360]

6.

Stępień K, Siudut J, Zalewski J, Nowakowski T, Undas A. Elevated plasma factor XI is associated with postthrombotic syndrome. Thromb Res. 2024 Sep;241:109086. [PubMed: 38968817]

7.

Visonà A, Quere I, Mazzolai L, Amitrano M, Lugli M, Madaric J, Prandoni P., European Society of Vascular Medicine (ESVM). Post-thrombotic syndrome. Vasa. 2021 Sep;50(5):331-340. [PubMed: 33720757]

8.

Yao J, Han M, Shi J, Wang W, Zhang J, Zhang Y. Prognosis and Factors 4 to 10 Years After Deep Vein Thrombosis: A Long-Term Follow-up Cohort Study. Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241266820. [PMC free article: PMC11375659] [PubMed: 39140994]

9.

Ariyanti F, Sukrisman L, Antono D, Harimurti K. The risk for post-thrombotic syndrome of subjects with deep vein thrombosis in an Indonesian referral hospital: a retrospective cohort study. Thromb J. 2023 Apr 05;21(1):38. [PMC free article: PMC10074643] [PubMed: 37020240]

10.

Prandoni P, Haas S, Fluharty ME, Schellong S, Gibbs H, Tse E, Carrier M, Jacobson B, Ten Cate H, Panchenko E, Verhamme P, Pieper K, Kayani G, Kakkar LA., GARFIELD-VTE investigators. Incidence and predictors of post-thrombotic syndrome in patients with proximal DVT in a real-world setting: findings from the GARFIELD-VTE registry. J Thromb Thrombolysis. 2024 Feb;57(2):312-321. [PMC free article: PMC10869374] [PubMed: 37932591]

11.

Yu T, Song J, Yu L, Deng W. A systematic evaluation and meta-analysis of early prediction of post-thrombotic syndrome. Front Cardiovasc Med. 2023;10:1250480. [PMC free article: PMC10484413] [PubMed: 37692043]

12.

Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH. Post-thrombotic syndrome: a clinical review. J Thromb Haemost. 2013 May;11(5):795-805. [PubMed: 23433231]

13.

Moustafa A, Alim HM, Chowdhury MA, Eltahawy EA. Postthrombotic Syndrome: Long-Term Sequela of Deep Venous Thrombosis. Am J Med Sci. 2018 Aug;356(2):152-158. [PubMed: 29779730]

14.

Farrell JJ, Sutter C, Tavri S, Patel I. Incidence and interventions for post-thrombotic syndrome. Cardiovasc Diagn Ther. 2016 Dec;6(6):623-631. [PMC free article: PMC5220207] [PubMed: 28123982]

15.

Khider L, Planquette B, Smadja DM, Sanchez O, Rial C, Goudot G, Messas E, Mirault T, Gendron N. Acute phase determinant of post-thrombotic syndrome: A review of the literature. Thromb Res. 2024 Jun;238:11-18. [PubMed: 38643521]

16.

DeMartino AG, Chatterjee D, De Ravin L, Babick O, Shiva A, Shah N, Nagarsheth K. Assessing the Predictive Value of the Neutrophil-to-Lymphocyte Ratio for Post-Thrombotic Syndrome following Iliofemoral Deep Venous Thrombosis. Ann Vasc Surg. 2025 Feb;111:393-401. [PubMed: 39617298]

17.

Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, Weitz JI., American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014 Oct 28;130(18):1636-61. [PubMed: 25246013]

18.

Lattimer CR, Kalodiki E, Azzam M, Geroulakos G. Validation of the Villalta scale in assessing post-thrombotic syndrome using clinical, duplex, and hemodynamic comparators. J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):8-14. [PubMed: 26992962]

19.

Vazquez SR, Kahn SR. Advances in the diagnosis and management of postthrombotic syndrome. Best Pract Res Clin Haematol. 2012 Sep;25(3):391-402. [PubMed: 22959554]

20.

Pop CT, Gu CS, Vedantham S, Galanaud JP, Kahn SR. Exploring the Villalta scale to capture postthrombotic syndrome using alternative approaches: A subanalysis of the ATTRACT trial. Res Pract Thromb Haemost. 2023 Jan;7(1):100032. [PMC free article: PMC10031339] [PubMed: 36970743]

21.

Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C., Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost. 2009 May;7(5):879-83. [PubMed: 19175497]

22.

Schropp L, Cats RB, de Kleijn RJCMF, van Hattum ES, Middeldorp S, Nijkeuter M, Westerink J, Petri BJ, de Borst GJ., Upper Extremity PTS group. The upper extremity postthrombotic syndrome score: an international Delphi consensus study to determine the score's functional disability component. Res Pract Thromb Haemost. 2023 Jan;7(1):100051. [PMC free article: PMC9982296] [PubMed: 36873563]

23.

de Kleijn RJCMF, Schropp L, van Hattum ES, Ünlu Ç, Middeldorp S, Nijkeuter M, Westerink J, Petri BJ, de Borst GJ. Post-thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study. J Thromb Haemost. 2022 Aug;20(8):1880-1886. [PMC free article: PMC9545993] [PubMed: 35608971]

24.

Su Y. QuickDASH. J Physiother. 2014 Sep;60(3):167. [PubMed: 25084628]

25.

Rabinovich A, Kahn SR. The postthrombotic syndrome: current evidence and future challenges. J Thromb Haemost. 2017 Feb;15(2):230-241. [PubMed: 27860129]

26.

Strijkers RH, de Wolf MA, Wittens CH. Risk factors of postthrombotic syndrome before and after deep venous thrombosis treatment. Phlebology. 2017 Jul;32(6):384-389. [PubMed: 27251397]

27.

Jasionowska S, Turner BRH, Machin M, Onida S, Gwozdz AM, Shalhoub J, Davies AH. Systematic review of exercise therapy in the management of post-thrombotic syndrome. Phlebology. 2022 Dec;37(10):695-700. [PMC free article: PMC9720701] [PubMed: 36164708]

28.

Kahn SR, Azoulay L, Hirsch A, Haber M, Strulovitch C, Shrier I. Acute effects of exercise in patients with previous deep venous thrombosis: impact of the postthrombotic syndrome. Chest. 2003 Feb;123(2):399-405. [PubMed: 12576357]

29.

Hansen D, Dendale P, Coninx K, Vanhees L, Piepoli MF, Niebauer J, Cornelissen V, Pedretti R, Geurts E, Ruiz GR, Corrà U, Schmid JP, Greco E, Davos CH, Edelmann F, Abreu A, Rauch B, Ambrosetti M, Braga SS, Barna O, Beckers P, Bussotti M, Fagard R, Faggiano P, Garcia-Porrero E, Kouidi E, Lamotte M, Neunhäuserer D, Reibis R, Spruit MA, Stettler C, Takken T, Tonoli C, Vigorito C, Völler H, Doherty P. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol. 2017 Jul;24(10):1017-1031. [PubMed: 28420250]

30.

Wu C, Li X, Zhao H, Ling Y, Ying Y, He Y, Zhang S, Liang S, Wei J, Gan X. Resistance exercise promotes the resolution and recanalization of deep venous thrombosis in a mouse model via SIRT1 upregulation. BMC Cardiovasc Disord. 2023 Jan 13;23(1):18. [PMC free article: PMC9837998] [PubMed: 36639616]

31.

Thieme D, Linnemann B, Mühlberg K, Noppeney T, Kreutz M, Thieme M. Compression Therapy in Acute Deep Venous Thrombosis of the Lower Limb and for the Prevention of Post-Thrombotic Syndrome—a Review Based on a Structured Literature Search. Dtsch Arztebl Int. 2024 Mar 22;121(6):188-194. [PMC free article: PMC11079798] [PubMed: 38260965]

32.

Appelen D, van Loo E, Prins MH, Neumann MH, Kolbach DN. Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev. 2017 Sep 26;9(9):CD004174. [PMC free article: PMC6483721] [PubMed: 28950030]

33.

O'Donnell MJ, McRae S, Kahn SR, Julian JA, Kearon C, Mackinnon B, Magier D, Strulovich C, Lyons T, Robinson S, Hirsh J, Ginsberg JS. Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial. Thromb Haemost. 2008 Mar;99(3):623-9. [PubMed: 18327413]

34.

Levi M. A long-awaited small step forward in the management of the post-thrombotic syndrome. Thromb Haemost. 2008 Mar;99(3):463-4. [PubMed: 18327391]

35.

Bonkemeyer Millan S, Gan R, Townsend PE. Venous Ulcers: Diagnosis and Treatment. Am Fam Physician. 2019 Sep 01;100(5):298-305. [PubMed: 31478635]

36.

Pishgahi M, Ghane Fard S, Lak Tabriz R, Karimi Toudeshki K, Talebi Z. The Effects of 3-Month Rosuvastatin Adjuvant Therapy on Post Thrombotic Syndrome following Deep Vein Thrombosis; a Randomized Clinical Trial. Arch Acad Emerg Med. 2023;11(1):e43. [PMC free article: PMC10440755] [PubMed: 37609533]

37.

Espitia O, Raimbeau A, Planquette B, Katsahian S, Sanchez O, Espinasse B, Bénichou A, Murris J. A systematic review and meta-analysis of the incidence of post-thrombotic syndrome, recurrent thromboembolism, and bleeding after upper extremity vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2024 Jan;12(1):101688. [PMC free article: PMC11523377] [PubMed: 37717788]

38.

Su YJ, Chang HY, Li YH. Endovascular Therapy for Venous Thromboembolic Diseases. Acta Cardiol Sin. 2021 Nov;37(6):566-573. [PMC free article: PMC8593485] [PubMed: 34812229]

39.

Philip VK, Yasir MB. Efficacy of Mechanical Thrombectomy in Preventing Post-Thrombotic Syndrome in Acute DVT: A Retrospective Study. Indian J Plast Surg. 2024 Jun;57(3):184-191. [PMC free article: PMC11319023] [PubMed: 39139687]

40.

Sang H, Li X, Qian A, Meng Q. Outcome of endovascular treatment in postthrombotic syndrome. Ann Vasc Surg. 2014 Aug;28(6):1493-500. [PubMed: 24727397]

41.

Vedantham S. Valvular dysfunction and venous obstruction in the post-thrombotic syndrome. Thromb Res. 2009;123 Suppl 4:S62-5. [PubMed: 19303507]

42.

Barbati ME, Avgerinos ED, Baccellieri D, Doganci S, Lichtenberg M, Jalaie H. Interventional treatment for post-thrombotic chronic venous obstruction: Progress and challenges. J Vasc Surg Venous Lymphat Disord. 2024 Sep;12(5):101910. [PMC free article: PMC11523345] [PubMed: 38777042]

43.

Shao J, Zhou Q, Jin F, Reissfelder C, Sigl M, Yagublu V, Keese M. A Systematic Review and Bayesian Network Meta-Analysis on the Effect of Different Anticoagulants on the Prophylaxis of Post-Thrombotic Syndrome after Deep Venous Thrombosis. J Clin Med. 2023 Nov 30;12(23) [PMC free article: PMC10706867] [PubMed: 38068502]

44.

Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol. 2009 May;145(3):286-95. [PubMed: 19222476]

45.

Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Mantovani LG, Prandoni P, Kakkar AK. Corrigendum to "Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE" [Thromb. Res. 2020 Jul; 191:103-112]. Thromb Res. 2022 Aug;216:129. [PubMed: 34863582]

46.

Zheng Y, Cao C, Chen G, Li S, Ye M, Deng L, Li Q. Analysis of risk factors for post-thrombotic syndrome after thrombolysis therapy for acute deep venous thrombosis of lower extremities. Int J Cardiol Cardiovasc Risk Prev. 2024 Sep;22:200319. [PMC free article: PMC11381788] [PubMed: 39253594]

Disclosure: Evelyn Calderon Martinez declares no relevant financial relationships with ineligible companies.

Disclosure: Rodolfo Garza Morales declares no relevant financial relationships with ineligible companies.